I would say they would be going for a regional Asia deal. The current trial is narmafotinib + gemcitabine/abraxane which is the chemotherapy regime traditionally used over here and Asia for pancreatic ca.
In the USA they use FOLFIRINOX, which we are planning to do a separate phase 2 trial with in 2025, hence I think any US deal/takeover would be post the FOLFIRINOX study if successful.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.005(3.03%) |
Mkt cap ! $43.96M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $26.76K | 164.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16598 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 37928 | 1 |
View Market Depth
| Last trade - 10.31am 11/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |